A Prospective, Multi-center, Cohort Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Therapy in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 13 Nov 2018
Price : $35 *
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B; Liver cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 26 Feb 2018 Planned End Date changed from 1 Jan 2021 to 8 Jan 2021.
- 26 Feb 2018 Planned primary completion date changed from 1 Jan 2021 to 2 Dec 2020.